IL1B and fatty liver disease: Consistent with the lower ALT levels, less hepatic steatosis, and higher AMPK activity, POA treatment reduced hepatic levels of the pro-inflammatory cytokines MCP-1 and TNF-α compared with OA treatment, while IL-1β remained unchanged (Fig. 3A).